Matinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis July 25, 2019 - NYSE Companies 0 » View More News for July 25, 2019